Translate Bio Announces Collaboration With Sanofi Pasteur to Develop Infectious Disease Vaccines

Translate Bio Announces Collaboration With Sanofi Pasteur to Develop Infectious Disease Vaccines

Firm News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Translate Bio, Inc., a clinical-stage mRNA therapeutics company developing a new class of medicines to treat diseases caused by protein or gene dysfunction, has entered into a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to five undisclosed infectious disease pathogens. Sanofi Pasteur, the vaccines global business unit of Sanofi (NYSE:SNY), will make an upfront payment of $45 million to Translate Bio, and the companies will conduct joint research and development activities to advance mRNA vaccines during an initial three-year research term.

The WilmerHale team representing Translate Bio in the collaboration agreement is led by Belinda Juran and Cynthia Mazareas, and includes Ariel Soiffer and Ryan Crane.

Read Translate Bio’s press release about the collaboration.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel